Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

PMID:
28978556
2.

Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary.

den Bakker CM, Smit JK, Bruynzeel AME, van Grieken NCT, Daams F, Derks S, Cuesta MA, Plukker JTM, van der Peet DL.

J Thorac Dis. 2017 Jul;9(Suppl 8):S843-S850. doi: 10.21037/jtd.2017.06.123.

3.

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.

Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, Rabkin CS, Bass AJ.

Oncotarget. 2016 May 31;7(22):32925-32. doi: 10.18632/oncotarget.9076.

4.

Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.

Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ.

Cancer Immunol Res. 2015 Oct;3(10):1123-1129. doi: 10.1158/2326-6066.CIR-15-0046. Epub 2015 Jun 16.

5.

Personalized cancer medicine: next steps in the genomic era.

Derks S, Diosdado B.

Cell Oncol (Dordr). 2015 Feb;38(1):1-2. doi: 10.1007/s13402-015-0221-0. Epub 2015 Feb 27. No abstract available.

6.

Mutational signatures in Helicobacter pylori-induced gastric cancer: lessons from new sequencing technologies.

Derks S, Bass AJ.

Gastroenterology. 2014 Aug;147(2):267-9. doi: 10.1053/j.gastro.2014.06.019. Epub 2014 Jun 25. No abstract available.

PMID:
24973679
7.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

8.

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Draht MX, Smits KM, Tournier B, Jooste V, Chapusot C, Carvalho B, Cleven AH, Derks S, Wouters KA, Belt EJ, Stockmann HB, Bril H, Weijenberg MP, van den Brandt PA, de Bruïne AP, Herman JG, Meijer GA, Piard F, Melotte V, van Engeland M.

Mol Oncol. 2014 May;8(3):679-88. doi: 10.1016/j.molonc.2014.01.011. Epub 2014 Feb 2.

9.

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M.

Cancer Metastasis Rev. 2014 Mar;33(1):161-71. doi: 10.1007/s10555-013-9462-4. Review.

10.

Analysis of promoter CpG island hypermethylation in cancer: location, location, location!

van Vlodrop IJ, Niessen HE, Derks S, Baldewijns MM, van Criekinge W, Herman JG, van Engeland M.

Clin Cancer Res. 2011 Jul 1;17(13):4225-31. doi: 10.1158/1078-0432.CCR-10-3394. Epub 2011 May 10.

11.

Colorectal cancer epigenetics: complex simplicity.

van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG.

J Clin Oncol. 2011 Apr 1;29(10):1382-91. doi: 10.1200/JCO.2010.28.2319. Epub 2011 Jan 10. Review.

PMID:
21220596
12.

Adeno-associated viral vector (AAV)-mediated gene transfer in the red nucleus of the adult rat brain: comparative analysis of the transduction properties of seven AAV serotypes and lentiviral vectors.

Blits B, Derks S, Twisk J, Ehlert E, Prins J, Verhaagen J.

J Neurosci Methods. 2010 Jan 15;185(2):257-63. doi: 10.1016/j.jneumeth.2009.10.009. Epub 2009 Oct 20.

PMID:
19850079
13.

Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.

Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruïne AP, Herman JG, van Engeland M.

Carcinogenesis. 2009 Jun;30(6):1041-8. doi: 10.1093/carcin/bgp073. Epub 2009 Mar 27.

PMID:
19329758
14.

Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations.

Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG, Weijenberg MP, de Bruïne AP, Meijer GA, van Engeland M.

Carcinogenesis. 2008 Feb;29(2):434-9. Epub 2007 Nov 28.

PMID:
18048385
15.

Down syndrome associated with hypothyroidism and chronic pericardial effusion: echocardiographic follow-up.

Said SA, Droste HT, Derks S, Gerrits CJ, Fast JH.

Neth Heart J. 2007;15(2):67-70.

16.

Promoter methylation precedes chromosomal alterations in colorectal cancer development.

Derks S, Postma C, Moerkerk PT, van den Bosch SM, Carvalho B, Hermsen MA, Giaretti W, Herman JG, Weijenberg MP, de Bruïne AP, Meijer GA, van Engeland M.

Cell Oncol. 2006;28(5-6):247-57.

17.

Methylation-specific PCR unraveled.

Derks S, Lentjes MH, Hellebrekers DM, de Bruïne AP, Herman JG, van Engeland M.

Cell Oncol. 2004;26(5-6):291-9. Review.

18.

Trustees and public policy.

Derks SM.

Trustee. 1989 Dec;42(12):16-7. No abstract available.

PMID:
10296613

Supplemental Content

Support Center